CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Insight Molecular Diagnostics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Insight Molecular Diagnostics Inc
2 International Plaza Dr. Suite 510
Phone: (615) 255-8880p:615 255-8880 NASHVILLE, TN  37217  United States Ticker: IMDXIMDX
Business Summary
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board AndrewArno 65 1/1/2023 6/1/2015
President, Chief Executive Officer, Director JoshuaRiggs 43 2/28/2023 12/2/2022
Chief Financial Officer Andrea S.James 43 6/17/2024 6/17/2024
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Chronix Biomedical 5941 Optical Court San Jose CA United States
Insight Genetics, Inc. 111 10th Ave South Nashville TN United States

Business Names
Business Name
Chronix Biomedical
Chronix Biomedical GmbH
Chronix Biomedical, Inc.
IMDX
Insight Genetics, Inc.
OCX

General Information
Number of Employees: 46 (As of 12/31/2024)
Outstanding Shares: 28,599,285 (As of 5/5/2025)
Shareholders: 182
Stock Exchange: NASD
Federal Tax Id: 271041563
Fax Number: (510) 521-3389
Email Address: info@OncoCyte.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, June 28, 2025